Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 6-8

  Sleijfer, S ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; PAZOPANIB; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; TRABECTEDIN;

ANGIOSARCOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LEIOMYOSARCOMA; MONOTHERAPY; MYXOSARCOMA; SCALP TUMOR; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIAS (EPIDEMIOLOGY); DEOXYCYTIDINE; DISEASE PROGRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SARCOMA; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 39149123128     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113414     Document Type: Editorial

References (16)

1. Sleijfer S, Seynaeve C, Verweij J: Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005;10:833-841.
2. Bramwell VHC, Anderson D, Charette ML: Doxorubicin-based chemotherapy for the palliative treatment of adults with locally advanced or metastatic soft tissue sarcoma. The Cochcrane Database of systematic reviews 2001; issue 4. Most recent amendment 27 july 2001.
3. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S: The pharmacalogic base ifosfamide use in adult patients with advamnced soft tissue sarcomas. The Oncologist 2007;12:1351-1360.
4. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichhardt P, Blay JY, Issels R, Van Oosterom A, Hogendoorn P, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: a randomised trial. Lancet 2004;364:1127-1134.
5. Fata F, O'Reilly E, Illson F, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-2037.
6. Grosso F, Jones RL, Demetri G, Judson I, Blay JY, LeCesne A, Sanfillipo R, Casierie P, Collini Dileo P, Spreafico C, Stachiotti S, Tamborini E, Tercero JC, Jimino J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602.
7. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marraeaud S, De brauwer A, Blay JY: Pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a phase II study from the EORTC STBSG (EORTC 62043). Annual Meeting Connective Tissue Oncol Soc 2007, abstr 875.
8. Isogai R, Kawada A, Aragana Y, Tezuka T: Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel. J Dermatol 2004;31:335-341
9. Maki R, Watjhen JK, Patel SR, Priebat DA, Okuno SH, Samulas B, Fanucchi M, Harmon DC, Schuetze SD, Reinke D, Thall PF, Benajmin RS, Baker LH, Hensley ML: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-2763.
10. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabatinni P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
11. Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M: Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie 2008;31: DOI: 10.1159/000111756.
12. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1999;17:150-167.
13. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weis GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
14. Escudier B, Eisen T, Stadler WM, Scszylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal cell carcinoma. New Engl J Med 2007;356:125-134.
15. Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 2002;38:543-549.
16. Van Glabbeke M, Steward W, Armand JP: Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer 2002;38:635-638.